Title of Collaborative Activity:
FDA/Center for Biologics and Evaluation and Research (CBER) Genomic Biologics
Description of Collaborative Activity:
--Protect and improve public and individual health in the US and, where feasible, globally --Facilitate development, approval and access to safe and effective products and promising new technologies
Type of Collaborative Activity:
Select Type of Collaborative Activity
Year the Collaborative Activity Originated:
2010
NIH Participating Institutes/Centers/Office of the Director:
NIAID
HHS Agency Collaborators on this Activity:
FDA
